MX349901B - Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. - Google Patents

Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.

Info

Publication number
MX349901B
MX349901B MX2013007847A MX2013007847A MX349901B MX 349901 B MX349901 B MX 349901B MX 2013007847 A MX2013007847 A MX 2013007847A MX 2013007847 A MX2013007847 A MX 2013007847A MX 349901 B MX349901 B MX 349901B
Authority
MX
Mexico
Prior art keywords
vegf antagonist
eye disorders
angiogenic eye
present
methods
Prior art date
Application number
MX2013007847A
Other languages
English (en)
Spanish (es)
Other versions
MX2013007847A (es
Inventor
D Yancopoulos George
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45507924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX349901(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2013007847A publication Critical patent/MX2013007847A/es
Publication of MX349901B publication Critical patent/MX349901B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2013007847A 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. MX349901B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161432245P 2011-01-13 2011-01-13
US201161434836P 2011-01-21 2011-01-21
US201161561957P 2011-11-21 2011-11-21
PCT/US2012/020855 WO2012097019A1 (en) 2011-01-13 2012-01-11 Use of a vegf antagonist to treat angiogenic eye disorders

Publications (2)

Publication Number Publication Date
MX2013007847A MX2013007847A (es) 2013-07-29
MX349901B true MX349901B (es) 2017-08-18

Family

ID=45507924

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013007847A MX349901B (es) 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
MX2017010249A MX385629B (es) 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX2021006092A MX2021006092A (es) 2011-01-13 2013-07-04 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017010249A MX385629B (es) 2011-01-13 2012-01-11 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX2021006092A MX2021006092A (es) 2011-01-13 2013-07-04 Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.

Country Status (13)

Country Link
US (14) US9254338B2 (cg-RX-API-DMAC7.html)
EP (4) EP4360709A3 (cg-RX-API-DMAC7.html)
JP (6) JP2014503555A (cg-RX-API-DMAC7.html)
KR (7) KR20210030510A (cg-RX-API-DMAC7.html)
CN (1) CN103533950A (cg-RX-API-DMAC7.html)
AU (5) AU2012205599B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013017752A8 (cg-RX-API-DMAC7.html)
CA (1) CA2824422A1 (cg-RX-API-DMAC7.html)
HK (1) HK1244693A1 (cg-RX-API-DMAC7.html)
IL (3) IL295359A (cg-RX-API-DMAC7.html)
MX (3) MX349901B (cg-RX-API-DMAC7.html)
SG (4) SG10201509193UA (cg-RX-API-DMAC7.html)
WO (1) WO2012097019A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016005381A1 (en) * 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN112826934A (zh) * 2014-12-11 2021-05-25 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
EP3261630A4 (en) * 2015-02-26 2018-10-10 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
WO2017046140A1 (en) * 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
EP3495023B1 (en) 2015-09-30 2020-04-22 Novaliq GmbH Semifluorinated compounds and their compositions
US20180353464A1 (en) 2015-11-24 2018-12-13 Indiana University Research And Technology Corporation Composition for blocking angiogenesis
EP4276199A3 (en) 2015-12-03 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
ES2886542T3 (es) 2016-05-25 2021-12-20 Santen Pharmaceutical Co Ltd Uso de sirolimus para tratar la degeneración macular asociada con la edad exudativa con edema persistente
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
WO2018140611A1 (en) * 2017-01-25 2018-08-02 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
JP2021503496A (ja) * 2017-11-16 2021-02-12 イヴェリック・バイオ・インコーポレイテッド 特発性ポリープ状脈絡膜血管症（ｉｐｃｖ）の処置方法又は予防方法
EP3713591A1 (en) 2017-11-20 2020-09-30 Just-Evotec Biologics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP4609914A3 (en) 2017-11-30 2025-10-15 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
KR20250166355A (ko) * 2018-02-06 2025-11-27 에프. 호프만-라 로슈 아게 안과 질환의 치료
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN111867631A (zh) * 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
CN116585466A (zh) 2018-05-10 2023-08-15 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
JP7561433B2 (ja) * 2019-05-28 2024-10-04 学校法人順天堂 糖尿病網膜症の予防又は治療薬
US20220306732A1 (en) * 2019-09-12 2022-09-29 Lupin Limited Modified dosing of vegf inhibitors for ophthalmic use
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
MX2022006241A (es) 2019-11-25 2022-08-22 Univ California Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.
IL293286A (en) 2019-12-06 2022-07-01 Regeneron Pharma vegf mini-traps and methods of using them
CA3159586A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
EP4164643A4 (en) * 2020-06-11 2024-07-03 Alkahest, Inc. METHODS OF IMPROVING THE OUTCOME OF RETINAL-ASSOCIATED DISEASE USING CCR3 INHIBITORS
WO2022186335A1 (ja) * 2021-03-03 2022-09-09 学校法人自治医科大学 副作用の予測方法およびそのための装置
WO2022221395A1 (en) * 2021-04-14 2022-10-20 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3190663A1 (en) * 2021-05-17 2022-11-24 Robert L. Vitti Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
WO2024168252A2 (en) * 2023-02-10 2024-08-15 Yale University Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy
US20250025531A1 (en) * 2023-06-23 2025-01-23 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
TW202525324A (zh) * 2023-08-17 2025-07-01 大陸商信達生物製藥（蘇州）有限公司 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
MXPA01012630A (es) 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
EA006746B1 (ru) 2001-11-09 2006-04-28 Айтек Фармасьютикалз Способы лечения глазных неоваскулярных заболеваний
JP2003309411A (ja) 2002-04-17 2003-10-31 Alps Electric Co Ltd 複合アンテナ
US7300563B2 (en) 2003-02-07 2007-11-27 Pavco, Inc. Use of N-alllyl substituted amines and their salts as brightening agents in nickel plating baths
MXPA05008972A (es) 2003-03-28 2005-11-04 Regeneron Pharma Metodos de tratamiento de diabetes por bloqueo de la actividad mediada por factor de crecimiento endotelial vascular.
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20040266688A1 (en) 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
CA2519835A1 (en) 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
ATE507240T1 (de) 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
KR100897379B1 (ko) 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
JP2008502738A (ja) 2004-06-10 2008-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
WO2006015297A2 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
EP2324848A3 (en) 2004-10-21 2011-09-14 Genentech, Inc. Method for treating intraocular neovascular diseases
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
PL2586459T3 (pl) 2005-03-25 2017-12-29 Regeneron Pharmaceuticals, Inc. Formulacje antagonistów vegf
KR20080033390A (ko) 2005-08-12 2008-04-16 리제네론 파라마큐티칼스 인코포레이티드 Ｖｅｇｆ 길항제로 질병을 치료하는 방법
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
US20100111963A1 (en) * 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
AU2015208482B2 (en) 2014-01-25 2017-02-02 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP4609914A3 (en) 2017-11-30 2025-10-15 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders

Also Published As

Publication number Publication date
KR20180023015A (ko) 2018-03-06
MX2013007847A (es) 2013-07-29
US10130681B2 (en) 2018-11-20
US11986511B2 (en) 2024-05-21
MX2021006092A (es) 2022-05-18
KR20220097542A (ko) 2022-07-07
JP2025169389A (ja) 2025-11-12
SG10202111177VA (en) 2021-11-29
EP3222285A1 (en) 2017-09-27
BR112013017752A8 (pt) 2018-01-09
JP2019167366A (ja) 2019-10-03
AU2024204677A1 (en) 2024-07-25
US20240123030A1 (en) 2024-04-18
AU2017200290A1 (en) 2017-02-02
US20180339018A1 (en) 2018-11-29
WO2012097019A1 (en) 2012-07-19
KR20200077622A (ko) 2020-06-30
US9669069B2 (en) 2017-06-06
US20210308217A1 (en) 2021-10-07
US20170202911A1 (en) 2017-07-20
US9254338B2 (en) 2016-02-09
US20220273764A1 (en) 2022-09-01
US11559564B2 (en) 2023-01-24
AU2019202260A1 (en) 2019-04-18
IL260167A (en) 2018-07-31
KR20210030510A (ko) 2021-03-17
JP2017061467A (ja) 2017-03-30
EP3763379A1 (en) 2021-01-13
US20210023173A1 (en) 2021-01-28
US12268730B2 (en) 2025-04-08
IL295359A (en) 2022-10-01
US20250152669A1 (en) 2025-05-15
CN103533950A (zh) 2014-01-22
NZ612593A (en) 2015-03-27
JP2024001190A (ja) 2024-01-09
AU2017200290B2 (en) 2019-01-03
US20210121524A1 (en) 2021-04-29
CA2824422A1 (en) 2012-07-19
JP2021193115A (ja) 2021-12-23
EP4360709A2 (en) 2024-05-01
MX385629B (es) 2025-03-18
US20190046609A1 (en) 2019-02-14
AU2021200935A1 (en) 2021-03-11
KR20240110092A (ko) 2024-07-12
SG10201509193UA (en) 2015-12-30
SG191334A1 (en) 2013-08-30
US11975045B2 (en) 2024-05-07
US11730794B2 (en) 2023-08-22
IL227160B (en) 2019-02-28
AU2012205599B2 (en) 2016-10-20
KR20140043313A (ko) 2014-04-09
EP2663325A1 (en) 2013-11-20
US20160101152A1 (en) 2016-04-14
EP4360709A3 (en) 2024-07-03
US11707506B2 (en) 2023-07-25
US10857205B2 (en) 2020-12-08
JP2014503555A (ja) 2014-02-13
HK1244693A1 (en) 2018-08-17
US20210308216A1 (en) 2021-10-07
US20130295094A1 (en) 2013-11-07
AU2012205599A1 (en) 2013-07-18
US10828345B2 (en) 2020-11-10
JP7733706B2 (ja) 2025-09-03
SG10201802789VA (en) 2018-05-30
BR112013017752A2 (pt) 2017-08-29
US20210085753A1 (en) 2021-03-25
KR20190049934A (ko) 2019-05-09
US11253572B2 (en) 2022-02-22
US20190247463A1 (en) 2019-08-15
US10888601B2 (en) 2021-01-12

Similar Documents

Publication Publication Date Title
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MY176514A (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX2016016836A (es) Metodos y dispositivos para tratar trastornos oculares posteriores.
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
HK1201438A1 (en) Treatment of ocular disease
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
MX2017005875A (es) Metodos para tratar enfermedades oculares.
EA201491711A1 (ru) Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
MX363822B (es) Formulaciones de liposomas.
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
MX2018000869A (es) Metodos para tratar trastornos asociados con la angiogenesis y la neovascularizacion.
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
EA201290603A1 (ru) Способ лечения
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
MX391627B (es) Aplicación cuantitativa periorbital de fármacos oftalmológicos.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
HRP20192256T1 (hr) Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta
HK1189820A (en) Use of a vegf antagonist to treat angiogenic eye disorders
AR102494A1 (es) Métodos para tratar enfermedades oculares
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
Park et al. Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

Legal Events

Date Code Title Description
FG Grant or registration